Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 5,308 matching trials from the live ClinicalTrials.gov search.

Filters: Louisville, Kentucky Clear all

Conditions: Pudendal Neuralgia, Chronic Pelvic Pain Syndrome
Interventions: Bupivacaine injection; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Large B-cell Lymphoma
Interventions: cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™; Genetic · Drug · Device
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 64
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 52 more

Conditions: Pneumococcal Immunization
Interventions: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 103
States / cities: Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 45
States / cities: Fayetteville, Arkansas • Encinitas, California • Fountain Valley, California + 38 more

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 47
States / cities: Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more

Conditions: Lymphoma
Interventions: filgrastim, ifosfamide, vinorelbine tartrate; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 101
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more

Conditions: Hyperlipidemia
Interventions: Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 35
States / cities: Birmingham, Alabama • Foley, Alabama • Phoenix, Arizona + 30 more

Conditions: Breast Cancer, Metastatic Cancer, Pain, Prostate Cancer
Interventions: pain therapy, radiation therapy; Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 949 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 234
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more

Conditions: Meibomian Gland Dysfunction
Interventions: AGN-195263 0.1%, AGN-195263 0.03%, AGN-195263 0.01%, AGN-195263 Vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 40 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 33
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Artesia, California + 29 more

Conditions: Hand-Foot Skin Reaction (HFSR)
Interventions: OQL011, Vehicle Ointment; Drug
Lead sponsor: OnQuality Pharmaceuticals (USA) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Goodyear, Arizona • Whittier, California • Aurora, Colorado + 12 more

Conditions: Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
Interventions: Eribulin mesylate; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Months to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 36 more

Conditions: OSA
Interventions: Aroxybutynin and Atomoxetine; Drug
Lead sponsor: Apnimed; Industry
Eligibility: 18 Years and older
Enrollment: 1,280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 93
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Chandler, Arizona + 80 more

Conditions: Atherosclerosis
Interventions: Darapladib, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 15,828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 155
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Interventions: HTD1801, Placebo; Drug
Lead sponsor: HighTide Therapeutics (Hong Kong) Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 43
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more

Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Interventions: Not listed
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 7,330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 65
States / cities: Phoenix, Arizona • Palo Alto, California • Pasadena, California + 51 more

Conditions: HIV, Cardiovascular Diseases
Interventions: Pitavastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 40 Years to 75 Years
Enrollment: 7,769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 91
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 59 more

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more

Conditions: Dermatomyositis
Interventions: human immunoglobulin G, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more

Conditions: Hematological Malignancies
Interventions: KPG-818; Drug
Lead sponsor: Kangpu Biopharmaceuticals, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Sacramento, California • Plantation, Florida • Louisville, Kentucky + 7 more

Conditions: Stomatitis
Interventions: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 41
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 37 more

Conditions: Scalp Psoriasis
Interventions: Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo; Drug
Lead sponsor: Glenmark Pharmaceuticals Ltd. India; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 31
States / cities: Encinitas, California • Fremont, California • San Diego, California + 25 more

Conditions: Cognitive Change
Interventions: Neuroblate System; Device
Lead sponsor: Monteris Medical; Industry
Eligibility: 16 Years and older
Enrollment: 81 participants
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Little Rock, Arkansas • Orlando, Florida • Kansas City, Kansas + 3 more

Conditions: Episodic Migraine
Interventions: Standard of Care (SOC) Migraine Preventive Medication, Atogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 112
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more

Conditions: Breast Cancer
Interventions: Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 28
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 22 more

Search by objective public record fields.

Transvaginal Versus Fluoroscopy-guided Trans Gluteal Pudendal Nerve Block for Pudendal Neuralgia

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Continuation Protocol for Obstructive Sleep Apnea (OSA)

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

PatiEnt Neuropsychological outcomeS After laseR Ablation

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]